首页> 外文期刊>AIDS >CD4(+) and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States
【24h】

CD4(+) and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States

机译:在美国围生期感染HIV的青年中,抗逆转录病毒疗法联合用药失败导致抗逆转录病毒疗法的CD4(+)和病毒载量转换策略

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: This study compared 12-month CD4(+) and viral load outcomes in HIV-infected children and adolescents with virological failure, managed with four treatment switch strategies.Design: This observational study included perinatally HIV-infected (PHIV) children in the Pediatric HIV/AIDS Cohort Study (PHACS) and Pediatric AIDS Clinical Trials (PACTG) Protocol 219C.Methods: Treatment strategies among children with virologic failure were compared: continue failing combination antiretroviral therapy (cART); switch to new cART; switch to drug-sparing regimen; and discontinue all ART. Mean changes in CD4(+)% and viral load from baseline (time of virologic failure) to 12 months follow-up in each group were evaluated using weighted linear regression models.Results: Virologic failure occurred in 939 out of 2373 (40%) children. At 12 months, children switching to new cART (16%) had a nonsignificant increase in CD4(+)% from baseline, 0.59 percentage points [95% confidence interval (95% CI) -1.01 to 2.19], not different than those who continued failing cART (71%) (-0.64 percentage points, P=0.15) or switched to a drug-sparing regimen (5%) (1.40 percentage points, P=0.64). Children discontinuing all ART (7%) experienced significant CD4(+)% decline -3.18 percentage points (95% CI -5.25 to -1.11) compared with those initiating new cART (P=0.04). All treatment strategies except discontinuing ART yielded significant mean decreases in log(10)VL by 12 months, the new cART group having the largest drop (-1.15 log(10)VL).Conclusion: In PHIV children with virologic failure, switching to new cART was associated with the best virological response, while stopping all ART resulted in the worst immunologic and virologic outcomes and should be avoided. Drug-sparing regimens and continuing failing regimens may be considered with careful monitoring.
机译:目的:本研究比较了采用病毒学控制的儿童和青少年的12个月CD4(+)和病毒载量的结果,并采用了四种治疗转换策略。设计:这项观察性研究纳入了围产期感染艾滋病毒(PHIV)的儿童。方法:比较了病毒学衰竭儿童的治疗策略:继续失败的联合抗逆转录病毒疗法(cART);儿童抗艾滋病毒队列研究(PHACS)和儿童艾滋病临床试验(PACTG)协议219C。切换到新的cART;改用保留药物的方案;并停止所有ART。使用加权线性回归模型评估每组从基线(病毒学衰竭时间)到随访12个月的CD4(+)%和病毒载量的平均变化。结果:2373人中有939人发生病毒学衰竭(40%)孩子们。在12个月时,换用新cART的儿童(16%)的CD4(+)%与基线相比无显着增加,为0.59个百分点[95%置信区间(95%CI)-1.01至2.19],与那些持续失败的cART(71%)(-0.64个百分点,P = 0.15)或改用药物保存方案(5%)(1.40个百分点,P = 0.64)。与开始新的cART的儿童相比,终止所有ART(7%)的儿童CD4(+)%下降显着-3.18个百分点(95%CI -5.25至-1.11)(P = 0.04)。除终止ART以外的所有治疗策略均使log(10)VL下降12个月,平均平均下降幅度最大,新的cART组下降幅度最大(-1.15 log(10)VL)。结论:在病毒学衰竭的PHIV儿童中,改用新的cART与最佳病毒学应答相关,而停止所有ART则导致最差的免疫和病毒学结果,应避免。谨慎监测可能会考虑保留药物方案和持续失败的方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号